Skip to main content

AstraZeneca and our year in brief

PRODUCT PERFORMANCE SUMMARY $M

NEXIUM -2%
2007 - 5,216, 2006 - 5,182, 2005 - 4,633		 SEROQUEL +15%
2007 - 4,027, 2006 - 3,416, 2005 - 2,761		 CRESTOR +33%
2007 - 2,796, 2006 - 2,028, 2005 - 1,268
ARIMIDEX +10%
2007 - 1,730, 2006 - 1,508, 2005 - 1,181		 SYMBICORT +22%
2007 - 1,575, 2006 - 1,184, 2005 - 1,006		 PULMICORT +10%
2007 - 1,454, 2006 - 1,292, 2005 - 1,162
SELOKEN/TOPROL-XL -22%
2007 - 1,438, 2006 - 1,795, 2005 - 1,735		 CASODEX +6%
2007 - 1,335, 2006 - 1,206, 2005 - 1,123		 ATACAND +9%
2007 - 1,287, 2006 - 1,110, 2005 - 974
LOSEC/PRILOSEC -20%
2007 - 1,143, 2006 - 1,371, 2005 - 1,652		 ZOLADEX +4%
2007 - 1,104, 2006 - 1,008, 2005 - 1,004		 MERREM +20%
2007 - 773, 2006 - 604, 2005 - 505
SYNAGIS1
2007 - 618		 FLUMIST1
2007 - 53		  

1Sales of MedImmune products are consolidated in AstraZeneca accounts from 1 June 2007. As a result, there are no prior period sales included.

Back to top ↑